The earnings call highlights BioLineRx's strong progress in expanding its pipeline and positive clinical data, alongside strategic restructuring and financial management, despite facing a net loss and decreased revenue year-over-year.

Company Guidance -

Q3 2025

During the BioLineRx Second Quarter 2025 Financial Results Conference Call, the company provided guidance on several key metrics. BioLineRx reported cash and equivalents of $28.2 million, extending their cash runway into the first half of 2027. They generated $1.7 million in sales for APHEXDA in Q2 2025, resulting in $0.3 million in royalty revenues. Research and development expenses were $2.3 million, reflecting a slight increase from the previous year due to costs associated with a PDAC study at Columbia University. BioLineRx also highlighted a reduction in operating cash burn by more than 70% after restructuring efforts post the Ayrmid transaction. The company is actively evaluating new assets for pipeline expansion, targeting an announcement this year, and emphasized their focus on early-stage oncology and rare disease assets for which they have significant expertise.

APHEXDA Sales and Royalty Revenue

In Q2 2025, APHEXDA generated sales of $1.7 million, resulting in $0.3 million of royalty revenues for BioLineRx.

Progress in Pipeline Expansion

BioLineRx is making excellent progress in evaluating early-stage oncology and rare disease assets, targeting a transaction this year.

Positive Data from PDAC Study

In the Columbia University PDAC study, 64% of patients showed partial response, and 91% had disease control, significantly better than historical rates.

Extended Cash Runway

BioLineRx extended its cash runway into the first half of 2027 with cash and equivalents of approximately $28.2 million.

Operational Restructuring

Implemented a broad restructuring resulting in a 70% reduction in operating cash burn.

Bioline Rx (IL:BLRX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

IL:BLRX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Dec 01, 2025	2025 (Q3)	-0.34 / -	0	―	―	―
Aug 14, 2025	2025 (Q2)	-0.34 / 0.00	0	―	―	―
May 27, 2025	2025 (Q1)	- / -	0	―	―	―
Mar 31, 2025	2024 (Q4)	-0.68 / 0.00	0	―	―	―
Nov 25, 2024	2024 (Q3)	-1.01 / 0.00	-6.753	―	―	―
Aug 15, 2024	2024 (Q2)	-1.69 / 0.00	-6.753	―	―	―
May 28, 2024	2024 (Q1)	-6.41 / 0.00	-3.376	―	―	―
Mar 26, 2024	2023 (Q4)	-5.06 / -4.39	-2.026	-116.67% (-2.36)	―	―
Nov 20, 2023	2023 (Q3)	-4.73 / -6.75	-3.376	-100.00% (-3.38)	―	―
Aug 30, 2023	2023 (Q2)	-3.71 / -6.75	-3.376	-100.00% (-3.38)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

IL:BLRX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 14, 2025	2.10	2.10	0.00%
May 27, 2025	2.20	2.00	-9.09%
Mar 31, 2025	1.90	1.90	0.00%
Nov 25, 2024	8.70	7.50	-13.79%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does BioLineRX Ltd. (IL:BLRX) report earnings?

BioLineRX Ltd. (IL:BLRX) is schdueled to report earning on Dec 01, 2025, Before Open (Confirmed).

What is BioLineRX Ltd. (IL:BLRX) earnings time?

BioLineRX Ltd. (IL:BLRX) earnings time is at Dec 01, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is the P/E ratio of BioLineRX Ltd. stock?

The P/E ratio of Bioline Rx is N/A.

What is IL:BLRX EPS forecast?

IL:BLRX EPS forecast for the fiscal quarter 2025 (Q3) is -0.34.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing